(Q51337873)

English

ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter].

scientific article published on 2 August 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

object named as

D R Matthews

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

author name string

S E Inzucchi

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

Position Statement Writing Group

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

publication date

2 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

55

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

10

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

2856-2857

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2669-Z

21 January 2018

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2669-Z

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2669-Z

21 January 2018

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22854891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A critique of the 2012 ADA/EASD position statement.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22854891

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-012-2669-Z

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22854891

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51337873&oldid=2210820641"